{
    "clinical_study": {
        "@rank": "134359", 
        "arm_group": [
            {
                "arm_group_label": "Telbivudine", 
                "arm_group_type": "Experimental", 
                "description": "Mother receives telbivudine 600mg per day. Infant receives standard immunoprophylaxis"
            }, 
            {
                "arm_group_label": "Lamivudine", 
                "arm_group_type": "Experimental", 
                "description": "Mother receives lamivudine 100mg per day. Infant receives standard immunoprophylaxis."
            }, 
            {
                "arm_group_label": "No antiviral treatment", 
                "arm_group_type": "No Intervention", 
                "description": "Mother receives no antiviral treatment. Infant receives standard immunoprophylaxis"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the efficacy and safety of telbivudine and\n      lamivudine use during late pregnancy for the prevention of HBV perinatal transmission in\n      highly viraemic mothers."
        }, 
        "brief_title": "Study of Telbivudine and Lamivudine to Prevent Vertical Transmission of Hepatitis B", 
        "completion_date": {
            "#text": "July 2013", 
            "@type": "Actual"
        }, 
        "condition": [
            "Chronic Hepatitis B", 
            "Late Pregnancy", 
            "Transmission", 
            "Complication"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis B", 
                "Hepatitis, Chronic", 
                "Hepatitis B, Chronic", 
                "Pregnancy, Prolonged"
            ]
        }, 
        "detailed_description": {
            "textblock": "This study enrolls HBV mono-infected pregnant women cohorts managed in outpatient\n      clinics/delivery unit at YouAn Hospital in Beijing. Subjects are prospectively followed from\n      gestation week 26 to postpartum week 52. Treatment na\u00efve mothers with HBV DNA > 6 log10 c/mL\n      and normal ALT are eligible. Mothers with abnormal fetus, cirrhosis or evidence of\n      hepatocellular carcinoma (HCC) are excluded. At gestation week 28, mothers will receive\n      telbivudine (LdT) 600 mg per day or lamivudine (Lam) 100 mg per day until postpartum 4 or no\n      treatment as per their preference. All infants will receive standard immunoprophylaxis. Data\n      is collected from patient records using data extraction forms. Primary endpoints are\n      vertical transmission rates at infants' age of 52 week and the safety of telbivudine or\n      lamivudine use."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Age: 20-40 years old\n\n          2. HBsAg, HBeAg positive and HBV DNA >6 log10 copies/ml\n\n          3. Gestational age: 26-28 weeks with normal fetus\n\n          4. Willing to consent for the study\n\n        Exclusion Criteria:\n\n          1. Elevated ALT\n\n          2. Antiviral treatment experience patients\n\n          3. Co-infection with HAV, HCV,HDV, HIV\n\n          4. Concurrent treatment with immune modulators, cytotoxic drugs, or steroids\n\n          5. Clinical signs of threatened miscarriage in early pregnancy\n\n          6. Clinical evidence of cirrhosis and/or hepatocellular carcinoma"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "40 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "700", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "December 3, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01743079", 
            "org_study_id": "20080810"
        }, 
        "intervention": [
            {
                "arm_group_label": "Telbivudine", 
                "description": "LdT 600mg QD", 
                "intervention_name": "Telbivudine", 
                "intervention_type": "Drug", 
                "other_name": "LdT"
            }, 
            {
                "arm_group_label": "Lamivudine", 
                "description": "LAM 100mg QD", 
                "intervention_name": "Lamivudine", 
                "intervention_type": "Drug", 
                "other_name": "LAM"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Lamivudine"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Telbivudine", 
            "Lamivudine", 
            "safety", 
            "efficacy", 
            "pregnancy"
        ], 
        "lastchanged_date": "July 29, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Beijing", 
                    "country": "China", 
                    "state": "Beijing", 
                    "zip": "100069"
                }, 
                "name": "Beijing YouAn Hospital"
            }
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "3", 
        "official_title": "The Efficacy and Safety of Telbivudine and Lamivudine Use in Highly Viremic Mothers to Prevent Hepatitis B Transmission", 
        "overall_official": [
            {
                "affiliation": "Division of Liver Diseases, Mount Sinai School of Medicine, Flushing, NY", 
                "last_name": "Calvin Pan, MD", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "Beijing YouAn Hospital", 
                "last_name": "Hua Zhang, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "China: Food and Drug Administration", 
                "China: Ethics Committee"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "July 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Safety on fetal exposure of telbivudine and lamivudine and vertical transmission rate from mother to child", 
            "safety_issue": "Yes", 
            "time_frame": "From gestation week 26 to postpartum week 52"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01743079"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Beijing YouAn Hospital", 
            "investigator_full_name": "Hua Zhang", 
            "investigator_title": "Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "percentage of mothers with serum HBV DNA level reduction, ALT within normal range and HBeAg and/or HBsAg negativity with or without seroconversion", 
            "safety_issue": "Yes", 
            "time_frame": "From gestation week 26 to pastpartume week 52"
        }, 
        "source": "Beijing YouAn Hospital", 
        "sponsors": {
            "collaborator": {
                "agency": "New Discovery LLC", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Beijing YouAn Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2009", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "July 2013"
    }
}